BCL2 and non-Hodgkin lymphoma: On the contrary, the highly selective Bcl2 inhibitor Venetoclax presented remarkable cytotoxic effects with significant reduced toxicity in comparison to dual Bcl2/Bcl-X inhibitors [136] in haematological malignancies, including acute myeloid leukemia (AML) [137,138] and non-Hodgkin lymphoma (NHL) [139].